PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Announces results from phase two study of LYT-100-COV on patients with post acute or long Covid with respiratory complications.
No treatment effect was observed in the patient population, however there was a reaffirmation of the safety and tolerability profile seen in prior studies.
As a result, PureTech will no longer pursue further studies in the current population, and will instead look to start studies of LYT-100 in idiopathic pulmonary fibrosis later in June.
Also on Tuesday, PureTech reveals its results from a healthy adult study of LYT-300, achieving the milestone of oral bioavailability of allopregnanolone in healthy adults.
"This is a key milestone for the candidate, which is designed to overcome the normally poor oral bioavailability of allopregnanolone to deliver its proven efficacy via simple, convenient oral dosing," the company says.
The clinical data establishes proof-of-principle for the company's Glyph platform for enabling oral administration of a range of therapeutics.
Current stock price: 157.00 pence, down 4.9% on Tuesday
12-month change: down 58%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)